Taraporevala Cyrus 4

What Happened Cyrus Taraporevala, a member of Pfizer’s Board of Directors, received an award of 1,543.845 phantom-share units on June 26, 2026. The units were valued at $24.29 each, for a total award value of $37,500. This was an award/compensation grant (transaction code A) — not an open-market purchase or sale.

Key Details

• Transaction date and price: 2026-06-26, 1,543.845 units at $24.29 per unit (total $37,500).
• Transaction type: Award/Grant of derivative units (phantom shares).
• Shares/units owned after transaction: Not reported in the filing.
• Footnotes: F1 — each unit represents one phantom share of common stock. F2 — these units are deferred director compensation (including dividend equivalents) and will be settled in cash or common stock at the director’s election following retirement from the Board.
• Filing timeliness: Form filed 2026-06-30 for a 2026-06-26 transaction (appears 4 days later); Form 4s are normally due within two business days, so this may be late.

Context This is a routine director compensation award in the form of phantom (deferred) shares. Such derivative awards are typically part of board pay and will be converted to cash or stock later, so they do not by themselves signal a buy/sell intent by the director.